Nab-paclitaxel — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	281	146	111	748	—	—	2003-09
Malignant Pancreatic Neoplasm	Phase4	Phase 4	87	40	23	230	—	—	Nov 1, 2006
Malignant Breast Neoplasm	Phase4	Phase 4	51	24	32	151	—	—	Jun 1, 2004
Malignant Lung Neoplasm	Phase4	Phase 4	46	22	21	110

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA Mutation1
Nab-paclitaxel	HER2-Positive Breast Carcinoma

Clinical trials

Trials with this intervention (753)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 751–753 of 753 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00479856	Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer	terminated	Phase 2	9	GlaxoSmithKlineINDUSTRY	1	Jun 5, 2012	clinicaltrials
NCT00307255	Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors	completed	Phase 1